Stocktoria
Apogee Therapeutics, Inc. APGE
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-07-14
Apogee Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $214.7M | $167.9M | $68.4M | $27.8M |
| Operating income | -$285.6M | -$216.9M | -$93.0M | -$30.7M |
| Income tax | $278,000 | $18,000 | $0 | — |
| Net income | -$255.8M | -$182.1M | -$84.0M | -$39.8M |
| EPS (diluted) | $-4.22 | $-3.30 | $-3.36 | $-16.16 |
| Operating cash flow | -$227.4M | -$171.2M | -$74.8M | -$16.4M |
| Free cash flow | -$232.6M | -$172.3M | -$74.9M | — |
| Cash & equivalents | $131.5M | $141.8M | $118.3M | $151.9M |
| Total assets | $937.1M | $754.0M | $401.4M | $152.1M |
| Total liabilities | $33.3M | $37.2M | $21.5M | $10.0M |
Source: SEC EDGAR filings · CIK 0001974640 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.